Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBITDA (2020 - 2025)

Historic EBITDA for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to -$2.6 million.

  • Burning Rock Biotech's EBITDA rose 5422.18% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.2 million, marking a year-over-year increase of 7324.32%. This contributed to the annual value of -$47.0 million for FY2024, which is 4860.9% up from last year.
  • Burning Rock Biotech's EBITDA amounted to -$2.6 million in Q3 2025, which was up 5422.18% from -$1.4 million recorded in Q2 2025.
  • Over the past 5 years, Burning Rock Biotech's EBITDA peaked at -$1.4 million during Q2 2025, and registered a low of -$43.3 million during Q4 2021.
  • In the last 5 years, Burning Rock Biotech's EBITDA had a median value of -$24.0 million in 2021 and averaged -$21.7 million.
  • As far as peak fluctuations go, Burning Rock Biotech's EBITDA tumbled by 25582.4% in 2021, and later surged by 9058.15% in 2025.
  • Over the past 5 years, Burning Rock Biotech's EBITDA (Quarter) stood at -$43.3 million in 2021, then grew by 25.59% to -$32.2 million in 2022, then grew by 27.75% to -$23.3 million in 2023, then skyrocketed by 55.68% to -$10.3 million in 2024, then skyrocketed by 74.82% to -$2.6 million in 2025.
  • Its EBITDA stands at -$2.6 million for Q3 2025, versus -$1.4 million for Q2 2025 and -$1.9 million for Q1 2025.